Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study.

Ther Adv Gastroenterol · 2019 · PMC6764033 · PMID 31598136

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

A nonsignificant trend toward better OS was observed in patients treated with FFX (14.0 months; 95% CI: 9.0–22.0) compared with the GN group (9.0 months; 95% CI: 7.0–13.0; HR = 0.67; 95% CI: 0.42–1.08; p log-rank = 0.097) ( Figure 2b ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.